Targeting myeloid checkpoint molecules in combination with antibody therapy: a novel anti-cancer strategy with iga antibodies?

HIGHLIGHTS

• who: Chilam Chan from the Erlangen-Nu00fcrnberg, Germany have published the Article: Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?, in the Journal: (JOURNAL)
• what: In this study, LILRB1 was shown to be more prevalent than LILRB2 in both healthy donor-derived macrophages and tumorassociated macrophages.
• future: Recent research has discovered that functional CD47-SIRPa interaction is crucial for the survival of T-and NK cells in a steady_state condition .

SUMMARY

Identifying and blocking checkpoint molecules on T_cells has evolved . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.